Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Therapeutic Advances in Gastroenterology Année : 2019

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience

Résumé

Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.

Dates et versions

hal-02549536 , version 1 (21-04-2020)

Identifiants

Citer

Ferdinando D’amico, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therapeutic Advances in Gastroenterology, 2019, 12, pp.175628481984863. ⟨10.1177/1756284819848631⟩. ⟨hal-02549536⟩
22 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More